RaQualia Pharma Inc. provided consolidated earnings guidance for the year ending December 31, 2024. For the year, the company expects net sales of JPY 4,535 million, operating profit of JPY 313 million and profit attributable to owners of parent of JPY 236 million or JPY 10.91 per basic share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
603 JPY | +0.84% | +0.33% | -12.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.35% | 80.21M | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- 4579 Stock
- News RaQualia Pharma Inc.
- RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2024